AI analyses photos of the eye that were taken with a retinal camera. These analyses are meant not only to screen for eye disease, but also those located throughout the body.
In fact, the AI can help clinicians screen for more than 140 eye and systemic conditions — some of them cardiovascular and neurological
The company Optain has gained an initial seed investment of $12 million and is an AI company meant to enable earlier disease detection and prevention through retinal imaging.
Some background:
👁️ there are a lot of camera companies out there that can shoot an image through the eye and look at the back of the eye, blood vessels, lesions, the optical nerve and various other features.
👁️ But not a lot of companies are very good at looking at that from an artificial intelligence and deep learning scenario to figure out which disease states we can predict or screen for by assessing those features.
👁️ The eye can often be a window to a person’s health
👁️ most clinicians lack non-invasive diagnostics and screenings that focus on the eye
👁️ adding a camera to Optain’s product could address this problem
Technology aspects:
📷Technology is based on technology developed by Mingguang He, an Australian clinician researcher
📷Eyetelligence’s technology
📷Eyetelligence’s AI was trained on third party cameras
📷Robust and flexible $15,000 cameras in optometry space
It’s difficult to say when Optain will clear regulatory hurdles and be able to enter the U.S. market, but Dunkel predicts this could happen in 2025. 📷💪
Here the Article by MedCityNews : https://medcitynews.com/2023/05/northwell-retinal-scan-eye-diagnosis-ai/
